-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On InMed Pharmaceuticals with Buy Rating, Announces Price Target of $42

Benzinga·11/09/2026 15:36:05
Diffusion vocale
Guggenheim analyst Seamus Fernandez initiates coverage on InMed Pharmaceuticals (NASDAQ:INM) with a Buy rating and announces Price Target of $42.